Yanagi Y - Search Results

1

Initial Characterization of the Epstein⁻Barr Virus BSRF1 Gene Product.

Yanagi Y, Masud HMAA, Watanabe T, Sato Y, Goshima F, Kimura H, Murata T. Yanagi Y, et al. Viruses. 2019 Mar 21;11(3):285. doi: 10.3390/v11030285. Viruses. 2019. PMID: 30901892 Free PMC article.

2

Molecular Basis of Epstein-Barr Virus Latency Establishment and Lytic Reactivation.

Murata T, Sugimoto A, Inagaki T, Yanagi Y, Watanabe T, Sato Y, Kimura H. Murata T, et al. Among authors: yanagi y. Viruses. 2021 Nov 23;13(12):2344. doi: 10.3390/v13122344. Viruses. 2021. PMID: 34960613 Free PMC article. Review.

3

Comprehensive Analyses of Intraviral Epstein-Barr Virus Protein-Protein Interactions Hint Central Role of BLRF2 in the Tegument Network.

Hara Y, Watanabe T, Yoshida M, Masud HMAA, Kato H, Kondo T, Suzuki R, Kurose S, Uddin MK, Arata M, Miyagi S, Yanagi Y, Sato Y, Kimura H, Murata T. Hara Y, et al. Among authors: yanagi y. J Virol. 2022 Jul 27;96(14):e0051822. doi: 10.1128/jvi.00518-22. Epub 2022 Jul 11. J Virol. 2022. PMID: 35862711 Free PMC article.

4

RNAseq analysis identifies involvement of EBNA2 in PD-L1 induction during Epstein-Barr virus infection of primary B cells.

Yanagi Y, Okuno Y, Narita Y, Masud HMAA, Watanabe T, Sato Y, Kanda T, Kimura H, Murata T. Yanagi Y, et al. Virology. 2021 May;557:44-54. doi: 10.1016/j.virol.2021.02.004. Epub 2021 Feb 21. Virology. 2021. PMID: 33639481 Free article.

5

A STING inhibitor suppresses EBV-induced B cell transformation and lymphomagenesis.

Miyagi S, Watanabe T, Hara Y, Arata M, Uddin MK, Mantoku K, Sago K, Yanagi Y, Suzuki T, Masud HMAA, Kawada JI, Nakamura S, Miyake Y, Sato Y, Murata T, Kimura H. Miyagi S, et al. Among authors: yanagi y. Cancer Sci. 2021 Dec;112(12):5088-5099. doi: 10.1111/cas.15152. Epub 2021 Oct 11. Cancer Sci. 2021. PMID: 34609775 Free PMC article.

6

PD-L1 upregulation by lytic induction of Epstein-Barr Virus.

Yanagi Y, Hara Y, Mabuchi S, Watanabe T, Sato Y, Kimura H, Murata T. Yanagi Y, et al. Virology. 2022 Mar;568:31-40. doi: 10.1016/j.virol.2022.01.006. Epub 2022 Jan 20. Virology. 2022. PMID: 35093708 Free article.

7

EBV Exploits RNA m⁶A Modification to Promote Cell Survival and Progeny Virus Production During Lytic Cycle.

Yanagi Y, Watanabe T, Hara Y, Sato Y, Kimura H, Murata T. Yanagi Y, et al. Front Microbiol. 2022 Jun 15;13:870816. doi: 10.3389/fmicb.2022.870816. eCollection 2022. Front Microbiol. 2022. PMID: 35783391 Free PMC article.

8

Antitumor activity of cyclin-dependent kinase inhibitor alsterpaullone in Epstein-Barr virus-associated lymphoproliferative disorders.

Watanabe T, Sato Y, Masud HMAA, Takayama M, Matsuda H, Hara Y, Yanagi Y, Yoshida M, Goshima F, Murata T, Kimura H. Watanabe T, et al. Among authors: yanagi y. Cancer Sci. 2020 Jan;111(1):279-287. doi: 10.1111/cas.14241. Epub 2019 Dec 11. Cancer Sci. 2020. PMID: 31743514 Free PMC article.

9

Epstein-Barr Virus BBRF2 Is Required for Maximum Infectivity.

Masud HMAA, Yanagi Y, Watanabe T, Sato Y, Kimura H, Murata T. Masud HMAA, et al. Among authors: yanagi y. Microorganisms. 2019 Dec 16;7(12):705. doi: 10.3390/microorganisms7120705. Microorganisms. 2019. PMID: 31888254 Free PMC article.

10

Role of Epstein-Barr Virus C Promoter Deletion in Diffuse Large B Cell Lymphoma.

Mabuchi S, Hijioka F, Watanabe T, Yanagi Y, Okuno Y, Masud HMAA, Sato Y, Murata T, Kimura H. Mabuchi S, et al. Among authors: yanagi y. Cancers (Basel). 2021 Feb 1;13(3):561. doi: 10.3390/cancers13030561. Cancers (Basel). 2021. PMID: 33535665 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

617 results

Search Page